KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Tax Provisions: 2018-2025

Historic Tax Provisions for Moderna (MRNA) over the last 6 years, with Sep 2025 value amounting to $13.0 million.

  • Moderna's Tax Provisions rose 62.50% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.0 million, marking a year-over-year decrease of 102.40%. This contributed to the annual value of -$46.0 million for FY2024, which is 105.96% down from last year.
  • Latest data reveals that Moderna reported Tax Provisions of $13.0 million as of Q3 2025, which was up 85.71% from $7.0 million recorded in Q2 2025.
  • Moderna's 5-year Tax Provisions high stood at $1.7 billion for Q3 2023, and its period low was -$384.0 million during Q1 2023.
  • Moreover, its 3-year median value for Tax Provisions was $7.0 million (2025), whereas its average is $75.3 million.
  • As far as peak fluctuations go, Moderna's Tax Provisions surged by 27,000.00% in 2021, and later tumbled by 233.21% in 2023.
  • Moderna's Tax Provisions (Quarterly) stood at $542.0 million in 2021, then tumbled by 64.94% to $190.0 million in 2022, then plummeted by 177.37% to -$147.0 million in 2023, then surged by 56.46% to -$64.0 million in 2024, then surged by 62.50% to $13.0 million in 2025.
  • Its Tax Provisions was $13.0 million in Q3 2025, compared to $7.0 million in Q2 2025 and $7.0 million in Q1 2025.